经导管三尖瓣置换术
曾经使用生物人工瓣膜 (BPV) 或组织瓣膜进行三尖瓣置换的患者，最终会不可避免地发生瓣膜衰竭。对于高危手术患者，经导管三尖瓣中瓣 (TVIV) 置换如今成为了一种普遍的干预手段，采用 Medtronic Melody™经导管肺瓣膜或 Edwards SAPIEN™经导管心瓣膜 (THV)。[48]Tzifa A, Momenah T, Al Sahari A, et al. Transcatheter valve-in-valve implantation in the tricuspid position. EuroIntervention. 2014;10:995-999.http://www.ncbi.nlm.nih.gov/pubmed/24755248?tool=bestpractice.com[49]Hoendermis ES, Douglas YL, van den Heuvel AF. Percutaneous Edwards SAPIEN valve implantation in the tricuspid position: case report and review of literature. EuroIntervention. 2012;8:628-633.http://www.ncbi.nlm.nih.gov/pubmed/22995090?tool=bestpractice.com先前植入的 BPV 框架为经导管瓣膜提供了良好环境，使进行干预的心脏病专家可以在旧的功能失调瓣膜孔内移植新的功能瓣膜，这样做的风险低于重做胸骨切开术和心肺转流术。[50]Cullen MW, Cabalka AK, Alli OO, et al. Transvenous, antegrade Melody valve-in-valve implantation for bioprosthetic mitral and tricuspid valve dysfunction: a case series in children and adults. JACC Cardiovasc Interv. 2013;6:598-605.http://www.ncbi.nlm.nih.gov/pubmed/23683739?tool=bestpractice.com[51]Roberts PA, Boudjemline Y, Cheatham JP, et al. Percutaneous tricuspid valve replacement in congenital and acquired heart disease. J Am Coll Cardiol. 2011;58:117-122.http://www.sciencedirect.com/science/article/pii/S0735109711013878http://www.ncbi.nlm.nih.gov/pubmed/21718905?tool=bestpractice.com
